Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGV005 in Refractory/Relapsed B-Cell Lymphoma
NCT07398963Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2026
- Primary completion
- Jul 2029
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RGV005 in B cell lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of dose limiting toxicity at 28 days. Started Feb 2026; status: recruiting.
02
Drugs
RGV005
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07398963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398963.